Forecasting Future Advances Across Oncology


Expert discuss their expectations for research and drug development in oncology in the new year.

Welcome to OncLive On Air! I’m your host today, Caroline Seymour.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with experts in breast, lung, genitourinary, and hematologic malignancies, to discuss key trends and anticipated advances for 2021 in oncology.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, chief medical officer and president of Clinical Operations at Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, and Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, were among those who forecast that the development of additional targeted and immune therapies are expected to permeate the oncology landscape across a broad range of malignancies in 2021.

Echoing such views were Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, first director of Clinical Cancer Genetics and professor of clinical medicine at the Albert Einstein College of Medicine, Neeraj Agarwal, MD, a professor of medicine and director of the Genitourinary Oncology Program at the Huntsman Cancer Institute, and Lori A. Leslie, MD, a hematology and oncology specialist at John Theurer Cancer Center.

In our exclusive interviews, each expert discussed their expectations for research and drug development in oncology in the new year.

Related Videos
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Dipti Patel-Donnelly, MD, Johns Hopkins
Saad J. Kenderian, MB, CHB
Jasmin M. Zain, MD
Wenxin (Vincent) Xu, MD,